ORIENT BIO (002630) Fundamentals 2026 — Revenue Analysis | SniperIQ
ORIENT BIO (002630) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩58.5B, trading at ₩986.00 on the KSC. This SniperIQ fundamentals page covers ORIENT BIO's valuation, profitability (net margin -15.3%), revenue (₩29.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is ORIENT BIO's market cap?
ORIENT BIO (002630) has a market capitalization of approximately ₩58.5B, trading at ₩986.00 on the KSC. Market cap moves with the live share price.
What is ORIENT BIO's P/E ratio?
ORIENT BIO's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is ORIENT BIO?
ORIENT BIO runs a net profit margin of -15.3%, a gross margin of 16.4%, and an operating margin of -14.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does ORIENT BIO generate?
ORIENT BIO reported revenue of ₩29.8B for fiscal year 2025, with net income of -₩4.6B and earnings per share (EPS) of -77.03. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does ORIENT BIO pay a dividend?
ORIENT BIO does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is ORIENT BIO financially healthy?
ORIENT BIO carries a debt-to-equity ratio of 0.03x and a current ratio of 7.82x, with a market beta of 0.04. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is ORIENT BIO a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For ORIENT BIO (002630) the key facts are: market cap ₩58.5B, revenue ₩29.8B, 52-week range 745-1632. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track ORIENT BIO's full fundamentals live
Get ORIENT BIO's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.